CL2011001004A1 - Compuestos derivados de n-(1h-indol-5-il)-ciclopropanocarboxamida, modulares abc; composicion farmaceutica; kit farmaceutico; y uso para tratar una afeccion enfermedad o trastorno tal como fibrosis quistica, enfisema hereditario, alzheimer, diabetes, entre otras. - Google Patents

Compuestos derivados de n-(1h-indol-5-il)-ciclopropanocarboxamida, modulares abc; composicion farmaceutica; kit farmaceutico; y uso para tratar una afeccion enfermedad o trastorno tal como fibrosis quistica, enfisema hereditario, alzheimer, diabetes, entre otras.

Info

Publication number: CL2011001004A1
Authority: CL; Chile
Prior art keywords: disease; abc; alzheimer; diabetes; disorder
Prior art date: 2008-11-06

Application number

CL2011001004A

Other languages

English (en)

Spanish (es)

Inventor

Sara S Hadida Ruah

Peter D J Grootenhuis

Mark T Mccartney Jason Miller

Goor Fredrick Numa Mehdi Michael Djamel Van

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-06

Filing date

2011-05-05

Publication date

2012-03-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42153560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001004(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-05 Application filed by Vertex Pharma filed Critical Vertex Pharma

2012-03-16 Publication of CL2011001004A1 publication Critical patent/CL2011001004A1/es

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
201000003883 Cystic fibrosis Diseases 0.000 title abstract 2
206010014561 Emphysema Diseases 0.000 title abstract 2
206010012601 diabetes mellitus Diseases 0.000 title abstract 2
201000010099 disease Diseases 0.000 title abstract 2
208000035475 disorder Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
150000002391 heterocyclic compounds Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Obesity (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)

CL2011001004A 2008-11-06 2011-05-05 Compuestos derivados de n-(1h-indol-5-il)-ciclopropanocarboxamida, modulares abc; composicion farmaceutica; kit farmaceutico; y uso para tratar una afeccion enfermedad o trastorno tal como fibrosis quistica, enfisema hereditario, alzheimer, diabetes, entre otras. CL2011001004A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11215208P	2008-11-06	2008-11-06

Publications (1)

Publication Number	Publication Date
CL2011001004A1 true CL2011001004A1 (es)	2012-03-16

Family

ID=42153560

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2011001004A CL2011001004A1 (es)	2008-11-06	2011-05-05	Compuestos derivados de n-(1h-indol-5-il)-ciclopropanocarboxamida, modulares abc; composicion farmaceutica; kit farmaceutico; y uso para tratar una afeccion enfermedad o trastorno tal como fibrosis quistica, enfisema hereditario, alzheimer, diabetes, entre otras.

Country Status (16)

Country	Link
EP (1)	EP2362874A2 (de)
JP (2)	JP2012508246A (de)
KR (1)	KR20110089170A (de)
CN (2)	CN102272128A (de)
AU (1)	AU2009313409A1 (de)
BR (1)	BRPI0921234B8 (de)
CA (2)	CA2948104C (de)
CL (1)	CL2011001004A1 (de)
IL (2)	IL212727A (de)
MX (1)	MX2011004834A (de)
NZ (2)	NZ610972A (de)
RU (2)	RU2011122646A (de)
SG (1)	SG10201501168RA (de)
UA (2)	UA104876C2 (de)
WO (1)	WO2010054138A2 (de)
ZA (1)	ZA201103856B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT2502911T (lt)	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
EP1945632B1 (de)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterozyklische modulatoren von atp-bindenden kassettentransportern
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US8969386B2 (en)	2007-05-09	2015-03-03	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
EP2639224B1 (de)	2007-12-07	2016-08-24	Vertex Pharmaceuticals Incorporated	Verfahren zur Herstellung von Cycloalkylcarboxamidopyridinbenzoesäuren
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
EP2365972B1 (de)	2008-11-06	2014-12-17	Vertex Pharmaceuticals Incorporated	Modulatoren von atp-bindenden kassettentransportern
UA104876C2 (uk) *	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
SI2408750T1 (sl)	2009-03-20	2015-11-30	Vertex Pharmaceuticals Incorporated	Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US20110251253A1 (en) *	2010-03-25	2011-10-13	Vertex Pharmaceuticals Incorporated	Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
HRP20211752T1 (hr)	2010-04-07	2022-02-18	Vertex Pharmaceuticals Incorporated	Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
CA2796642A1 (en) *	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
NZ603044A (en) *	2010-04-22	2015-08-28	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
AU2011242454A1 (en) *	2010-04-22	2012-11-08	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CA2808501A1 (en)	2010-08-23	2012-03-01	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
AR085509A1 (es)	2011-03-09	2013-10-09	Bayer Cropscience Ag	Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
WO2013112804A1 (en)	2012-01-25	2013-08-01	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670A1 (de)	2012-02-27	2015-01-07	Vertex Pharmaceuticals Incorporated	Pharmazeutische zusammensetzung und verabreichung davon
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
TWI692469B (zh)	2012-11-09	2020-05-01	南韓商Ｌｇ化學股份有限公司	Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
ITMI20122065A1 (it)	2012-12-03	2014-06-04	Univ Padova	Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2970468B1 (de)	2013-03-13	2021-07-07	Novartis AG	Notch2-bindungsmoleküle zur behandlung von atemwegserkrankungen
JP6963896B2 (ja)	2013-11-12	2021-11-10	バーテックスファーマシューティカルズインコーポレイテッドVertex Pharmaceuticals Incorporated	Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
EP2878339A1 (de)	2013-12-02	2015-06-03	Siena Biotech S.p.A.	SIP3-Antagonisten
AR099336A1 (es)	2014-02-17	2016-07-13	Bayer Cropscience Ag	Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
EP2932966A1 (de)	2014-04-16	2015-10-21	Novartis AG	Gammasekretasehemmer zur Behandlung von Atemwegserkrankungen
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
TWI735416B (zh)	2014-10-06	2021-08-11	美商維泰克斯製藥公司	囊腫纖維化症跨膜傳導調節蛋白之調節劑
KR20170063954A (ko)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
PT3221692T (pt)	2014-11-18	2021-09-10	Vertex Pharma	Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
EP3240539A4 (de)	2014-12-31	2018-07-25	Auspex Pharmaceuticals, Inc.	Cyclopropanecarboxamidmodulatoren des cftr- regulators
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
HK1249893A1 (zh)	2015-03-31	2018-11-16	Vertex Pharmaceuticals (Europe) Limited	氘代vx-661
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
US10047077B2 (en)	2016-04-13	2018-08-14	Skyline Antiinfectives, Inc.	Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
SI3519401T1 (sl)	2016-09-30	2022-01-31	Vertex Pharmaceuticals Incorporated	Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
CN110267948B (zh)	2016-12-09	2023-12-08	弗特克斯药品有限公司	囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
TWI799435B (zh)	2017-08-02	2023-04-21	美商維泰克斯製藥公司	製備化合物之製程
US10654829B2 (en)	2017-10-19	2020-05-19	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko)	2017-12-08	2024-10-14	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
AU2019222758B2 (en)	2018-02-15	2022-07-07	Vertex Pharmaceuticals Incorporated	Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
EP3774825A1 (de)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulatoren des transmembranleitfähigkeitsreglers von zystischer fibrose, pharmazeutische zusammensetzungen, behandlungsverfahren und verfahren zur herstellung des modulators
CN109651160B (zh) *	2019-01-25	2021-08-13	上海应用技术大学	一种催化苯乙炔氢胺化反应制备烯胺类化合物的方法
CN111763198B (zh) *	2019-04-01	2021-09-07	新发药业有限公司	一种5-取代环丙基甲酰氨基吲哚衍生物的制备方法
TWI848092B (zh)	2019-04-03	2024-07-11	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白調節劑
CA3150162A1 (en)	2019-08-14	2021-02-18	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
CN112624956A (zh) *	2019-10-08	2021-04-09	兰州大学	3-吲哚磺酸衍生物新型制备方法
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en)	2020-08-13	2023-04-01	Vertex Pharma	Crystal forms of CFTR modulators
EP4225762A1 (de)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulatoren des regulators der transmembran-leitfähigkeit bei zystischer fibrose
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en)	2020-12-10	2023-07-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CN118047762B (zh) *	2024-03-25	2024-12-06	深圳菲斯生物科技有限公司	一种利扎曲普坦ep杂质c的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
WO2004035571A1 (en) *	2002-10-15	2004-04-29	Rigel Pharmaceuticals, Inc.	Substituted indoles and their use as hcv inhibitors
ZA200602755B (en) *	2003-09-06	2007-06-27	Vertex Pharma	Modulators of ATP-binding cassette transporters
LT2502911T (lt)	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
NZ571803A (en) *	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
UA104876C2 (uk) *	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
EP2365972B1 (de) *	2008-11-06	2014-12-17	Vertex Pharmaceuticals Incorporated	Modulatoren von atp-bindenden kassettentransportern
US20110098311A1 (en) *	2009-10-22	2011-04-28	Vertex Pharmaceuticals Incorported	Compositions for treatment of cystic fibrosis and other chronic diseases

2008
- 2008-11-12 UA UAA201106975A patent/UA104876C2/uk unknown
2009
- 2009-06-11 UA UAA201106976A patent/UA110192C2/uk unknown
- 2009-11-06 CN CN2009801539702A patent/CN102272128A/zh active Pending
- 2009-11-06 MX MX2011004834A patent/MX2011004834A/es active IP Right Grant
- 2009-11-06 KR KR1020117012767A patent/KR20110089170A/ko not_active Ceased
- 2009-11-06 AU AU2009313409A patent/AU2009313409A1/en not_active Abandoned
- 2009-11-06 WO PCT/US2009/063475 patent/WO2010054138A2/en not_active Ceased
- 2009-11-06 NZ NZ610972A patent/NZ610972A/en not_active IP Right Cessation
- 2009-11-06 RU RU2011122646/04A patent/RU2011122646A/ru not_active Application Discontinuation
- 2009-11-06 CN CN201610012624.4A patent/CN105693701B/zh active Active
- 2009-11-06 EP EP09795592A patent/EP2362874A2/de not_active Withdrawn
- 2009-11-06 SG SG10201501168RA patent/SG10201501168RA/en unknown
- 2009-11-06 NZ NZ592693A patent/NZ592693A/xx not_active IP Right Cessation
- 2009-11-06 BR BRPI0921234A patent/BRPI0921234B8/pt active IP Right Grant
- 2009-11-06 JP JP2011535676A patent/JP2012508246A/ja not_active Withdrawn
- 2009-11-06 CA CA2948104A patent/CA2948104C/en active Active
- 2009-11-06 CA CA2742980A patent/CA2742980A1/en not_active Abandoned
2011
- 2011-05-05 IL IL212727A patent/IL212727A/en active IP Right Grant
- 2011-05-05 CL CL2011001004A patent/CL2011001004A1/es unknown
- 2011-05-25 ZA ZA2011/03856A patent/ZA201103856B/en unknown
2014
- 2014-08-07 IL IL233996A patent/IL233996A/en active IP Right Grant
- 2014-09-30 RU RU2014139599A patent/RU2014139599A/ru not_active Application Discontinuation
- 2014-11-25 JP JP2014237756A patent/JP2015061860A/ja active Pending

Also Published As

Publication number	Publication date
CA2948104C (en)	2017-09-12
IL233996A0 (en)	2014-09-30
RU2014139599A (ru)	2016-04-20
BRPI0921234B1 (pt)	2021-06-22
JP2015061860A (ja)	2015-04-02
NZ610972A (en)	2014-11-28
ZA201103856B (en)	2012-02-29
SG10201501168RA (en)	2015-04-29
BRPI0921234B8 (pt)	2022-07-19
IL233996A (en)	2015-09-24
BRPI0921234A2 (pt)	2016-02-23
EP2362874A2 (de)	2011-09-07
KR20110089170A (ko)	2011-08-04
NZ592693A (en)	2013-05-31
CN102272128A (zh)	2011-12-07
CA2742980A1 (en)	2010-05-14
UA110192C2 (uk)	2015-12-10
CN105693701A (zh)	2016-06-22
IL212727A (en)	2014-08-31
HK1226076A1 (zh)	2017-09-22
AU2009313409A1 (en)	2010-05-14
CA2948104A1 (en)	2010-05-14
UA104876C2 (uk)	2014-03-25
RU2011122646A (ru)	2012-12-20
MX2011004834A (es)	2011-07-28
IL212727A0 (en)	2011-07-31
WO2010054138A3 (en)	2010-11-11
CN105693701B (zh)	2021-08-10
WO2010054138A2 (en)	2010-05-14
JP2012508246A (ja)	2012-04-05

Publication	Publication Date	Title
CL2011001004A1 (es)	2012-03-16	Compuestos derivados de n-(1h-indol-5-il)-ciclopropanocarboxamida, modulares abc; composicion farmaceutica; kit farmaceutico; y uso para tratar una afeccion enfermedad o trastorno tal como fibrosis quistica, enfisema hereditario, alzheimer, diabetes, entre otras.
CL2011001027A1 (es)	2012-03-02	Compuestos derivados de 1-(benzo[d][1,3]dioxol-6-il]-n(1h-indol-5-il)ciclopropano carboxamida; moduladores abc; composicion farmaceutica que los comprende; metodo in vitro de incremento de transportadores abc; kit farmaceutico; y su uso en el tratamiento de fibrosis quisticas, problemas metabolicos, del snc, entre otros.
CY1112921T1 (el)	2016-04-13	Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
CL2011000919A1 (es)	2012-01-06	Compuestos derivados de n-fenil-4-oxo-(1,4-dihidroquinolin o 1h-quinolin)-3-carboxamida, moduladores del regulador de conductancia transmembrana de fibrosis quistica (cftr); compuestos intermediarios; composicion farmaceutica; kit farmaceutico; proceso de preparacion; y uso para el tratamiento de fibrosis quistica, diabetes, entre otros.
CL2009000035A1 (es)	2009-11-27	Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
NO20081975L (no)	2008-06-02	Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
EA201170703A1 (ru)	2012-01-30	Производные адамантилбензамида
CL2011000835A1 (es)	2011-07-22	Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
DK1863812T3 (da)	2010-10-18	Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
CL2007002610A1 (es)	2008-02-01	Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2009001059A1 (es)	2010-11-12	Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
EA200702498A1 (ru)	2008-06-30	N-(пиридин-2-ил)сульфонамидные производные
CL2011001658A1 (es)	2011-11-11	Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
CL2013003598A1 (es)	2014-07-11	Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
ATE447568T1 (de)	2009-11-15	Neue pyrinderivate
GEP20125487B (en)	2012-04-25	Organic compounds and their use
UY30759A1 (es)	2008-07-31	Compuestos quimicos
CL2012001250A1 (es)	2012-11-30	Compuestos derivados de espirooxoindol, antagonista de la interaccion entre p53 y mdm2; composición farmacéutica que lo comprende; a un kit farmacéutico; uso en el tratamiento del cancer.
CL2008001560A1 (es)	2009-05-22	Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
CL2008001303A1 (es)	2008-11-14	Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer.
ES2421613T3 (es)	2013-09-04	Composición farmacéutica externa
NO20062689L (no)	2006-09-12	Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
CL2008003284A1 (es)	2009-05-15	Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
CL2007002689A1 (es)	2008-04-18	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
NO341679B1 (no)	2017-12-18	Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren